BreStem is a clinical stage biotech company working to fight deadly lung diseases through stem cell and exosome therapies. The company’s lead candidate BRS101(autologous lung spheroid cells) has gained FDA approval as the world’s first IND using intrinsic lung-derived cells to treat pulmonary conditions. The company’s second candidate BRS201 (lung spheroid secretome/exosome) is currently at the preIND development stage.
WHAT WE DO
BreStem is at the forefront of a revolution in lung regeneration therapy. Lung Spheroid Cells (LSCs) therapy have shown to be effective in preclinical studies of pulmonary fibrosis and may have wide applications as an anti-inflammatory and anti-fibrotic treatment, with the potential to cure pulmonary fibrosis. In addition, we are developing cell-free strategies (using secertome and exosome) derived from lung stem cells for off-the-shelf and non-invasive regenerative therapies.